Author asks whether NTLA can squeeze after positive FDA trial feedback and high short interest.
NTLA — LONG Author notes NTLA has ~38% short interest and just received positive FDA feedback to restart its trial. They argue this combination should push the stock up via a short squeeze.
their Short interest is at ~38% and just got positive feedback from FDA, for restarting their trial, which should push this up